Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luke Mitcheson

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Eclinicalmedicine|December 4, 2023
Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trialJohn Marsden, Mike Kelleher, Eilish Gilvarry, et al.
Trials|August 19, 2022
Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadoneJohn Marsden, Mike Kelleher, Zoë Hoare, et al.
Harm Reduction Journal|April 23, 2017
Monitoring quality and coverage of harm reduction services for people who use drugs: a consensus studyLucas Wiessing, Marica Ferri, Vendula Běláčková, et al.
BMJ Open|July 2, 2021
Using a pragmatically adapted, low-cost contingency management intervention to promote heroin abstinence in individuals undergoing treatment for heroin use disorder in UK drug services (PRAISE): a cluster randomised trialNicola Metrebian, Tim Weaver, Kimberley Goldsmith, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Eclinicalmedicine|December 4, 2023
Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trialJohn Marsden, Mike Kelleher, Eilish Gilvarry, et al.
Trials|August 19, 2022
Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadoneJohn Marsden, Mike Kelleher, Zoë Hoare, et al.
Harm Reduction Journal|April 23, 2017
Monitoring quality and coverage of harm reduction services for people who use drugs: a consensus studyLucas Wiessing, Marica Ferri, Vendula Běláčková, et al.
BMJ Open|July 2, 2021
Using a pragmatically adapted, low-cost contingency management intervention to promote heroin abstinence in individuals undergoing treatment for heroin use disorder in UK drug services (PRAISE): a cluster randomised trialNicola Metrebian, Tim Weaver, Kimberley Goldsmith, et al.
Pageof 4